epocrates

CagriSema shows superior glycemic, weight loss benefits in phase 3 trial

February 5, 2026

Novo Nordisk’s phase 3 REIMAGINE 2 trial (NCT06065540) demonstrated that once‑weekly CagriSema (cagrilintide/semaglutide) achieved superior reductions in HbA1c and body weight compared with semaglutide alone across all tested doses. Adults with a mean baseline HbA1c of 8.2% saw reductions of up to 1.91 percentage points after 68 weeks of CagriSema 2.4 mg/2.4 mg compared with 1.76 percentage points with semaglutide 2.4 mg. Participants with an average baseline body weight of 101 kg experienced up to 14.2% weight loss with the combination therapy vs. 10.2% with semaglutide alone. No weight‑loss plateau was observed for CagriSema at week 68. In the 2.4 mg/2.4 mg group, 43% of participants achieved at least 15% weight loss and 24% reached at least 20%. Safety findings were consistent with incretin‑ and amylin‑based therapies, with adverse events primarily mild to moderate and gastrointestinal in nature.

Clinical takeaway: CagriSema may offer clinicians a potent single‑injection option to improve both HbA1c and weight outcomes in adults with type 2 diabetes, pending full phase 3 data and regulatory review.

Source:

Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial. [News release]. 2026. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916481